Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3049% below fair value
$1.24−0.08 (-6.44%)
Close on Nov 17, 2026Market cap $5.68MP/E –Yield –
Biomerica cash
Cash and short-term investments held at the end of each period.
Biomerica's cash was $2.73M at Aug 31, 2026. For fiscal 2026 it was $1.31M, down 45.5% from the year before. Over ten years it grew -3.6% a year on average. The highest annual figure on record is $9.72M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $1.31M | -45.5% |
| FY2025 | May 31, 2025 | $2.40M | -42.5% |
| FY2024 | May 31, 2024 | $4.17M | -57.1% |
| FY2023 | May 31, 2023 | $9.72M | +64.3% |
| FY2022 | May 31, 2022 | $5.92M | +40.9% |
| FY2021 | May 31, 2021 | $4.20M | -51.4% |
| FY2020 | May 31, 2020 | $8.64M | +1158.2% |
| FY2019 | May 31, 2019 | $686.79K | -43.0% |
| FY2018 | May 31, 2018 | $1.20M | -1.7% |
| FY2017 | May 31, 2017 | $1.23M | -35.1% |
| FY2016 | May 31, 2016 | $1.89M | +73.6% |
| FY2015 | May 31, 2015 | $1.09M | -27.9% |
| FY2014 | May 31, 2014 | $1.51M | -38.9% |
| FY2013 | May 31, 2013 | $2.47M | +129.2% |
| FY2012 | May 31, 2012 | $1.08M | +8.9% |
| FY2011 | May 31, 2011 | $989.27K | -6.2% |
| FY2010 | May 31, 2010 | $1.06M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $2.73M | -10.5% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $1.31M | -45.5% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $1.34M | -56.3% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $2.54M | +7.2% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $3.05M | +8.3% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $2.40M | -42.5% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $3.06M | -42.5% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $2.37M | -66.8% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $2.82M | -64.7% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $4.17M | -57.1% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $5.32M | +59.0% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $7.13M | +40.8% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $7.99M | +31.5% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $9.72M | +64.3% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $3.35M | -67.1% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $5.07M | -29.6% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $6.08M | +21.6% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $5.92M | +40.9% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $10.17M | +93.0% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $7.20M | +26.7% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $5.00M | -28.3% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $4.20M | -51.4% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $5.27M | +120.4% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $5.68M | +567.9% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $6.96M | +762.4% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $8.64M | +1158.2% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $2.39M | +160.6% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $850.99K | -24.4% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $807.55K | +38.4% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $686.79K | -43.0% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $917.94K | +53.8% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $1.12M | +37.6% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $583.69K | -46.0% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $1.20M | -1.7% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $597.03K | -61.3% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $817.81K | -49.2% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $1.08M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $1.23M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $1.54M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $1.61M | – |
See a number that looks wrong?